Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AMLIOTCMKTS:BFGCDOTCMKTS:LIACFOTCMKTS:LXRP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMLIAmerican Lithium$0.26+2.1%$0.26$0.32▼$1.11$81.77M1.41571,671 shs126,300 shsBFGCDAugusta Gold$1.02+7.9%$0.79$0.29▼$2.79$61.93M1.1966,177 shs66,995 shsLIACFAmerican Lithium$0.26+2.1%$0.26$1.20▼$3.50$604.98M1.48432,060 shs126,300 shsLXRPLexaria Bioscience$0.00$0.17▼$0.56$20.15MN/A608,350 shs2.15 million shs10 Stocks Set to Soar in Summer 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMLIAmerican Lithium+2.10%+6.14%-0.60%-5.60%-53.95%BFGCDAugusta Gold0.00%+12.03%+39.73%+39.73%+45.71%LIACFAmerican Lithium+2.10%+6.14%-0.60%-5.60%-53.95%LXRPLexaria Bioscience0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAMLIAmerican LithiumN/AN/AN/AN/AN/AN/AN/AN/ABFGCDAugusta GoldN/AN/AN/AN/AN/AN/AN/AN/ALIACFAmerican LithiumN/AN/AN/AN/AN/AN/AN/AN/ALXRPLexaria BioscienceN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMLIAmerican Lithium 0.00N/AN/AN/ABFGCDAugusta Gold 0.00N/AN/AN/ALIACFAmerican Lithium 0.00N/AN/AN/ALXRPLexaria Bioscience 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMLIAmerican LithiumN/AN/AN/AN/A$0.58 per shareN/ABFGCDAugusta GoldN/AN/AN/AN/AN/AN/ALIACFAmerican LithiumN/AN/AN/AN/A$0.75 per shareN/ALXRPLexaria Bioscience$380K0.00N/AN/A$0.03 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMLIAmerican Lithium-$29.55M-$0.10N/AN/AN/AN/A-17.25%-16.87%N/ABFGCDAugusta GoldN/A-$0.12N/A∞N/AN/AN/AN/AN/ALIACFAmerican Lithium-$18.80M-$0.11N/A∞N/AN/A-16.28%-15.96%N/ALXRPLexaria Bioscience-$4.09MN/A0.00N/AN/A-1,046.77%-157.62%-148.09%N/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAMLIAmerican LithiumN/AN/AN/AN/AN/ABFGCDAugusta GoldN/AN/AN/AN/AN/ALIACFAmerican LithiumN/AN/AN/AN/AN/ALXRPLexaria BioscienceN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMLIAmerican LithiumN/A4.234.23BFGCDAugusta GoldN/AN/AN/ALIACFAmerican LithiumN/A22.7622.76LXRPLexaria Bioscience0.018.528.01Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMLIAmerican Lithium7.70%BFGCDAugusta GoldN/ALIACFAmerican Lithium0.01%LXRPLexaria Bioscience0.11%Insider OwnershipCompanyInsider OwnershipAMLIAmerican LithiumN/ABFGCDAugusta Gold13.03%LIACFAmerican LithiumN/ALXRPLexaria BioscienceN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMLIAmerican LithiumN/A217.93 millionN/ANot OptionableBFGCDAugusta Gold760.72 millionN/ANot OptionableLIACFAmerican LithiumN/A208.61 millionN/ANot OptionableLXRPLexaria Bioscience489.59 millionN/ANot OptionableLXRP, AMLI, BFGCD, and LIACF HeadlinesRecent News About These CompaniesLEXX: GLP-1-H25-5 Study CompleteJune 16, 2025 | msn.comLexaria Bioscience to Engage with Industry Leaders at BIO International ConventionJune 5, 2025 | tipranks.comLexaria Bioscience Stock Price, Quotes and Forecasts | NASDAQ:LEXXW | BenzingaMay 21, 2025 | benzinga.comLexaria Bioscience Corp.: Lexaria Provides Update on Material Transfer Agreement with Pharmaceutical CompanyMay 13, 2025 | finanznachrichten.deLexaria Advances Collaboration with Pharma Partner on Drug Delivery TechnologyMay 12, 2025 | tipranks.comLexaria Bioscience Announces Closing of $2 Million Registered Direct Offering of Common StockMay 1, 2025 | bctechnology.comBLexaria Bioscience Corp.: Lexaria Announces Closing of $2 Million Registered Direct Offering of Common StockApril 28, 2025 | finanznachrichten.deLexaria Bioscience Secures $2 Million in Direct Stock OfferingApril 28, 2025 | tipranks.comLexaria Bioscience Secures $2 Million in Direct Stock OfferingApril 25, 2025 | tipranks.comLexaria Bioscience Corp.: Lexaria Announces $2 Million Registered Direct Offering of Common StockApril 25, 2025 | finanznachrichten.deLEXX: Second Quarter ResultsApril 24, 2025 | msn.comLexaria Bioscience Corp.: Lexaria's Human GLP-1 Study #5 Begins DosingApril 2, 2025 | finanznachrichten.deLexaria's DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly’s Injectable Weight Loss Drug Zepbound(R)March 21, 2025 | bctechnology.comBLexaria Bioscience announces PK results on DehydraTech-Tirzepatide oral capsulesMarch 19, 2025 | markets.businessinsider.comLexaria's DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly’s Injectable Zepbound(R)March 18, 2025 | finance.yahoo.comLexaria Bioscience Corp.: Lexaria's DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly's Injectable ZepboundMarch 18, 2025 | finanznachrichten.deLexaria Bioscience Corp.: Lexaria's Strategic Business Pursuit of DehydraTECH-LiraglutideFebruary 20, 2025 | finanznachrichten.deLexaria Bioscience stock hits 52-week low at $1.62February 11, 2025 | msn.comLexaria reports promising drug delivery study resultsJanuary 30, 2025 | msn.comLexaria CEO says FY25 R&D will ‘remain concentrated’ on GLP-1 investigationsJanuary 30, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir SoonIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseIntel's Turnaround Strategy Shifts From Planning to Attack ModeBy Jeffrey Neal Johnson | June 20, 2025View Intel's Turnaround Strategy Shifts From Planning to Attack ModeOuster Soars 27% as DoD Grants First 3D LiDAR Approval for DronesBy Leo Miller | June 14, 2025View Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for DronesLXRP, AMLI, BFGCD, and LIACF Company DescriptionsAmerican Lithium NASDAQ:AMLI$0.26 +0.01 (+2.08%) As of 07/2/2025American Lithium Corp., an exploration and development stage company, engages in the acquisition, exploration, and development of resource properties in the United States. It principally focuses on the TLC Lithium Project located in the town of Tonopah, Nevada; and the Falchani Lithium project and the Macusani Uranium project located in Puno, Peru. The company was formerly known as Menika Mining Ltd. and changed its name to American Lithium Corp. in April 2016. American Lithium Corp. was incorporated in 1974 and is based in Vancouver, Canada.Augusta Gold OTCMKTS:BFGCD$1.02 +0.07 (+7.86%) As of 07/1/2025Augusta Gold Corp., a junior exploration company, engages in the acquisition and exploration of mineral properties in the United States. It primarily explores for gold, silver, and other metals. The company holds interests in the Bullfrog gold project located in the Bullfrog Hills of Nye County, Nevada. It also owns, controls, or has acquired mineral rights on Federal patented and unpatented mining claims in the state of Nevada for the purpose of exploration and potential development of metals on a total of approximately 7,800 acres of land. The company was formerly known as Bullfrog Gold Corp. and changed its name to Augusta Gold Corp. in January 2021. Augusta Gold Corp. was incorporated in 2007 and is headquartered in Vancouver, Canada.American Lithium OTCMKTS:LIACF$0.26 +0.01 (+2.08%) As of 07/2/2025American Lithium Corp., an exploration stage company, engages in the identification, acquisition, exploration, and development of resource properties in the United States. It principally focuses on the TLC Claystones project covering an area of approximately 5,052 hectares located in the town of Tonopah, Nevada; and the Falchani Lithium project and the Macusani Uranium project located in Puno, Peru. The company was formerly known as Menika Mining Ltd. and changed its name to American Lithium Corp. in April 2016. American Lithium Corp. was incorporated in 1974 and is headquartered in Vancouver, Canada.Lexaria Bioscience OTCMKTS:LXRPLexaria Bioscience Corp. operates in the drug delivery platform business. It develops and out-licenses its DehydraTECH technology for the delivery of bioactive compounds that promotes healthy ingestion methods, lower overall dosing, and higher effectiveness in active molecule delivery. The company has licensed DehydraTECH to various companies operating in the nicotine, pharmaceutical, nutraceutical, and vitamin industries. Lexaria Bioscience Corp. was founded in 2004 and is headquartered in Kelowna, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case Nike's Stock Just Got an Upgrade: Is a Real Comeback Brewing? Why Hims & Hers Is a Buy Below $35 After Its 16% Pullback Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
